Ray Yin

Dr. Ray Yin, co-founder of Fulgent Therapeutics (later split into Fulgent Genetics and Fulgent Pharma), is the president and CSO of Fulgent Pharma. Dr. Yin previously worked at the US Army Research Laboratory managing its nanobiotechnology for chemical and biological defense program, as well as serving as a scientific advisor on various DoD/Joint Service/DARPA/NATO programs and committees. Dr. Yin is a world class expert, a prolific inventor, and an accomplished entrepreneur in the nanobiotechnology area receiving a variety of US and international patents and awards. Some of the major awards include three consecutive US Army R&D Achievement Awards, an AAPS Annual Award, and a National Tibbetts Award. As the Principal Investigator, Dr. Yin successfully led the development of a number of nanotechnology-based products from concept creation to final product fielding/commercialization. These include the first nanotechnology-based rapid multiplexed biological agent detection system currently fielded by DoD, the commercialization of an FDA EUA authorized COVID-19 antigen rapid test supported under the NIH/RADx initiative, as well as a 1st -in-class nano-drug delivery system that has achieved US FDA DMF status with a clinical stage drug currently under development. Dr. Yin received his Ph.D. in chemistry from the University of Southern California.